Colchicine as Treatment for People With Hand Osteoarthritis

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

100 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-01-15

Study Completion Date

2022-08-03

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The study aims to compare oral colchicine 0.5 mg administered two times daily for 12 weeks with placebo as a treatment of hand OA symptoms.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Colchicine for Symptom and Inflammation in Knee Osteoarthritis

NCT02176460

Knee Osteoarthritis

COMPLETED PHASE2/PHASE3

Metformin Treatment of Patients with Hand Osteoarthritis

NCT06367283

Hand Osteoarthritis

RECRUITING PHASE3

Efficacy and Safety of Diclofenac Sodium Gel in Hand Osteoarthritis

NCT00171652

Osteoarthritis

COMPLETED PHASE3

Efficacy and Safety of Diclofenac Sodium Gel in Hand Osteoarthritis

NCT00171665

Osteoarthritis

COMPLETED PHASE3

The Study to Evaluate Efficacy and Safety of Celecoxib Capsule in Hand Osteoarthritis Patients

NCT03067194

Osteoarthritis Hand

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Osteoarthritis Hand Osteoarthritis Finger

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Colchicine

Tablet colchicine 0.5 mg administered two times daily

Group Type EXPERIMENTAL

Colchicine 0.5 MG

Intervention Type DRUG

The intervention tablets are commercially available Colchicine "Tiofarma"

Placebo

Tablet placebo administered two times daily

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Encapsulated placebo tablets. Placebo is identical to the active intervention.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Colchicine 0.5 MG

The intervention tablets are commercially available Colchicine "Tiofarma"

Intervention Type DRUG

Placebo

Encapsulated placebo tablets. Placebo is identical to the active intervention.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Age ≥18 years.
2. Hand OA according to the ACR criteria above.
3. Hand OA finger pain: Pain at rest ≥40 mm on VAS (0 to 100 mm range).

Exclusion Criteria

Comorbidities

1. Other known medical disease that may affect joints, e.g. RA, gout, PsA
2. Positive anti-cyclic citrullinated peptide (\>10 kU/L)
3. Known cutaneous deposition diseases (e.g. amyloidosis or porphyria).
4. Known blood dyscrasias and coagulation disorders
5. Known malignancy (except successfully treated squamous or basal cell skin carcinoma)
6. Elevated alanine transaminase (\>45 U/L females, \>70 U/L for males)
7. Creatinine clearance ≤60 ml/min
8. Elevated creatine kinase (\>210 U/L females, \>280 U/L for males)
9. Known allergies towards the interventions
10. Drug or alcohol abuse in the last year
11. Generalised pain syndromes such as fibromyalgia
12. Current reflux
13. Current or recurrent diarrhoeal illnesses
14. Current abdominal pain
15. Known peripheral neuropathies
16. Any other condition or impairment that, in the opinion of the investigator, makes a potential participant unsuitable for participation or which obstruct participation, such as e.g. psychiatric disorders.

Medical history
17. History of hand surgery within 12 months prior enrolment.
18. History of arthroplasty or arthrodesis in the hand Management strategies
19. Treatment with P-glycoprotein inhibitors and/or cytochrome P450 3A4 (CYP3A4) inhibitors, see section "Colchicine safety in drug-drug interactions" and table 7. If potential participants have been treated with these pharmaceuticals previously, treatment must be terminated 5 half-lifes before initiation of study drug.
20. Use of systemic corticosteroids equivalent of ≥ 7.5 mg prednisolone daily within 3 months.
21. Participation in experimental device or experimental drug study 3 months prior to enrolment.
22. Intra-articular treatments or aspirations of any kind of any joint in the hands 3 months before inclusion
23. Intra-articular corticosteroids into any joint 1 months before inclusion
24. Current use of synthetic or non-synthetic opioids
25. Scheduled surgery during study participation
26. Planning to start other treatment for hand OA in the study participation period.

Reproductive system
27. Pregnancy.
28. Planned pregnancy within the study period, 3 months after end of study treatment for female fertile participant and 6 months after end of study treatment for male participant.
29. Insufficient anti-conception therapy for female fertile participants within the study period and 3 months after end of study treatment. Sufficient anti-conception therapy consists of intra-uterine device (coil),hormonal anti-conception (birth control pills, implant, intra-uterine system, dermal patch, vaginal ring, or injections) or sexual abstinence Female participants are considered infertile if they are postmenopausal or if they have undergone surgical sterilisation (bilateral salpingectomy, hysterectomy or bilateral oophorectomy). Postmenopausal state is defined as no menses for 12 months without alternative medical cause before inclusion in the study. Menopause state will be confirmed by measurement of follicle stimulating hormone.
30. Insufficient anti-conception therapy for male participants within the study period and 6 months after end of study treatment. Sufficient anti-conception therapy consists of condom or sexual abstinence. Male participants are considered sterile if they have undergone surgical sterilisation (vasectomy).
31. Breast-feeding

A target hand will be selected for outcome assessment once individual fulfills in- and exclusions criterias. Selection of the target hand will adhere to the following, with advancement to next step if unable to choose target hand based on the given criteria.

1. The hand with most overall pain, assessed by VAS finger joint pain.
2. The hand with most overall reduced function, assessed by AUSCAN function subscale.
3. The hand with most overall stiffness, assessed by AUSCAN stiffness subscale.
4. The hand with most swollen joints, assessed by physician joint count.
5. The hand with most tender joints, assessed by physician joint count.
6. The hand with highest summed radiographic score, assessed by radiographic scoring of conventional X-ray.
7. If unable to select target hand based on the above criteria, a target hand will be randomly assigned.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No